Novavax Inc NVAX.O stated on Monday that an prolonged evaluation of a late-stage research carried out in the UK confirmed that its COVID-19 vaccine offered long-term safety in opposition to the coronavirus.
The protein-based vaccine, NVX-CoV2373, continued to supply safety and maintained total efficacy of 82.7% over a six-month interval, the corporate stated.
Moreover, vaccine efficacy of 82.5% was maintained in opposition to each symptomatic and asymptomatic an infection, whereas vaccine efficacy in opposition to extreme illness was 100%.
The evaluation was carried out between November 2020 and Might 2021 earlier than the Delta and Omicron variants turned dominant.
Novavax is engaged on creating an Omicron-specific vaccine and stated on Monday it expects to start manufacturing doses of the shot at a business scale within the first quarter.
The corporate didn't disclose what number of total doses it expects to ship within the first quarter, however forecast US$4 billion to $5 billion in total income in 2022.
Final yr, Novavax reported knowledge from its U.Okay. trial, the place the vaccine was 89.3% efficient in stopping COVID-19, with circumstances collected over three months.
"The vaccine presents safety in opposition to symptomatic and asymptomatic COVID-19 an infection which can each interrupt virus transmission and stop COVID-19 illness," stated Gregory Glenn, president of analysis and growth.
"Moreover, we're inspired to see that our COVID-19 vaccine maintains a excessive stage of sturdy efficacy and continues to exhibit a reassuring security profile on this prolonged timeframe."
Earlier this month, Britain permitted the two-dose COVID-19 vaccine to be used in adults. The vaccine is being reviewed by the U.S. Meals and Drug Administration and has obtained approvals from the European Union and the World Well being Group in addition to nations together with India, Indonesia and the Philippines.
The corporate earlier this month stated its vaccine was about 80% efficient in a late-stage trial in adolescents.
(Reporting by Mrinalika Roy in Bengaluru and Carl O'Donnell in New York; Enhancing by Maju Samuel)